These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19023036)

  • 1. Antibiotic prophylaxis for chronic obstructive pulmonary disease: resurrecting an old idea.
    Kunisaki KM; Niewoehner DE
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1098-9. PubMed ID: 19023036
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations.
    Seemungal TA; Wilkinson TM; Hurst JR; Perera WR; Sapsford RJ; Wedzicha JA
    Am J Respir Crit Care Med; 2008 Dec; 178(11):1139-47. PubMed ID: 18723437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Contribution to a debate on Cochrane analysis].
    Frimodt-Møller N
    Ugeskr Laeger; 2007 Jun; 169(24):2343. PubMed ID: 17607862
    [No Abstract]   [Full Text] [Related]  

  • 4. Are prophylactic antibiotics useful in chronic obstructive pulmonary disease?
    Arenas A; Rada G
    Medwave; 2015 Nov; 15 Suppl 3():e6309. PubMed ID: 26571418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotic prevention of acute exacerbations of COPD.
    Wenzel RP; Fowler AA; Edmond MB
    N Engl J Med; 2012 Jul; 367(4):340-7. PubMed ID: 22830464
    [No Abstract]   [Full Text] [Related]  

  • 6. [Sparse effect of long-term treatment with macrolides in patients with chronic obstructive pulmonary disease].
    Jersild Jespersen M; Mygind LH; Vestbo J; Sonne J
    Ugeskr Laeger; 2013 Mar; 175(10):648-51. PubMed ID: 23462037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic antibiotic therapy in chronic obstructive pulmonary disease.
    Maraffi T; Piffer F; Cosentini R
    Ther Adv Respir Dis; 2010 Jun; 4(3):135-42. PubMed ID: 20530062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Azithromycin: We're there!
    Albert RK; Connett J; Criner GL; Han M;
    Am J Respir Crit Care Med; 2014 Nov; 190(9):1074-5. PubMed ID: 25360732
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply: Azithromycin: We're there!
    Restrepo MI; Anzueto A
    Am J Respir Crit Care Med; 2014 Nov; 190(9):1075-6. PubMed ID: 25360733
    [No Abstract]   [Full Text] [Related]  

  • 10. Antibiotics as immunomodulant agents in COPD.
    Blasi F; Mantero M; Aliberti S
    Curr Opin Pharmacol; 2012 Jun; 12(3):293-9. PubMed ID: 22321568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preventing COPD exacerbations with macrolides: a review and budget impact analysis--author response to letter to the editor.
    Simoens S; Laekeman G; Decramer M
    Respir Med; 2014 Jul; 108(7):1065. PubMed ID: 24849292
    [No Abstract]   [Full Text] [Related]  

  • 12. [The role of macrolides in treatment of exacerbations of chronic obstructive pulmonary disease].
    Targowski T; Jahnz-Rózyk K
    Pol Merkur Lekarski; 2010 Apr; 28(166):311-4. PubMed ID: 20491344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clarithromycin in coronary heart disease: excess mortality in the long term.
    Prescrire Int; 2006 Dec; 15(86):225. PubMed ID: 17167932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Emergence of macrolide resistant Streptococcus pyogenes strains in pediatric patients in France].
    Mariani-Kurkdjian P; Doit C; Deforche D; Brahimi N; Francois M; Van den Abbeele T; Bingen E
    Pathol Biol (Paris); 2004 Oct; 52(8):489-92. PubMed ID: 15465270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan: a retrospective multicenter analysis.
    Yamaya M; Azuma A; Tanaka H; Takizawa H; Chida K; Taguchi Y; Mikasa K; Kadota J; Kudoh S
    J Am Geriatr Soc; 2008 Jul; 56(7):1358-60. PubMed ID: 18774970
    [No Abstract]   [Full Text] [Related]  

  • 16. Meta-analysis of bacterial resistance to macrolides.
    Halpern MT; Schmier JK; Snyder LM; Asche C; Sarocco PW; Lavin B; Nieman R; Mandell LA
    J Antimicrob Chemother; 2005 May; 55(5):748-57. PubMed ID: 15772147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments.
    Cameron EJ; McSharry C; Chaudhuri R; Farrow S; Thomson NC
    Clin Exp Allergy; 2012 Sep; 42(9):1302-12. PubMed ID: 22925316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic resistance in sputum isolates of Streptococcus pneumoniae in chronic obstructive pulmonary disease is related to antibiotic exposure.
    Desai H; Richter S; Doern G; Heilmann K; Dohrn C; Johnson A; Brauer A; Murphy T; Sethi S
    COPD; 2010 Oct; 7(5):337-44. PubMed ID: 20854048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral bacterial vaccines for the prevention of acute exacerbations in chronic obstructive pulmonary disease and chronic bronchitis.
    Arandjus C; Black PN; Poole PJ; Wood Baker R; Steurer-Stey C
    Respir Med; 2006 Oct; 100(10):1671-81. PubMed ID: 16934969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria.
    Nseir S; Ader F
    Curr Opin Pulm Med; 2008 Mar; 14(2):95-100. PubMed ID: 18303416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.